Showing results (1-10 of 307) with videos related to
Sort By:
Pageof 31
Therapeutic Advances in Neurological Disorders|December 25, 2010
Improving symptom control in early Parkinson's diseaseStuart H Isaacson, Robert A HauserCases Journal|October 16, 2009
Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case seriesKapil D Sethi, Robert A Hauser, Stuart H Isaacson, et al.Clinical Parkinsonism & Related Disorders|July 27, 2023
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatmentStuart H Isaacson, Robert A Hauser, Rajesh Pahwa, et al.Clinical Neuropharmacology|June 23, 2016
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic HypotensionRobert A Hauser, Stephane Heritier, Gerald J Rowse, et al.Journal of Parkinson'S Disease|March 27, 2023
Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?Robert A Hauser, William G Ondo, Yi Zhang, et al.Neurology and Therapy|February 2, 2022
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label TreatmentRobert A Hauser, Antonella Favit, L Arthur Hewitt, et al.The Journal of Clinical Psychiatry|January 10, 2020
Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson DiseaseStuart H IsaacsonThe American Journal of Managed Care|January 21, 2016
Managed care approach to the treatment of neurogenic orthostatic hypotensionStuart H IsaacsonThe Journal of Clinical Psychiatry|January 10, 2020
Early Recognition and Diagnosis of Parkinson Disease and Ongoing AssessmentsStuart H IsaacsonJournal of Parkinson'S Disease|August 5, 2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyRobert A Hauser, Rajesh Pahwa, Caroline M Tanner, et al.Pageof 31